CASI Pharmaceuticals, Inc. (CASIF)
OTCMKTS · Delayed Price · Currency is USD
0.1300
+0.0225 (20.93%)
At close: Jun 5, 2026
CASI Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 20.71 | 28.54 | 33.88 | 43.11 | 30.17 | |
Revenue Growth (YoY) | -27.42% | -15.77% | -21.41% | 42.89% | 99.25% |
Cost of Revenue | 10.64 | 17.39 | 13.83 | 15.83 | 12.56 |
Gross Profit | 10.08 | 11.15 | 20.05 | 27.28 | 17.61 |
Selling, General & Admin | 46.61 | 41.44 | 41.84 | 37.78 | 38.41 |
Research & Development | 6.31 | 8.92 | 9.86 | 16 | 14.42 |
Other Operating Expenses | - | -0 | -6.37 | - | - |
Operating Expenses | 52.92 | 50.36 | 45.33 | 53.77 | 52.83 |
Operating Income | -42.85 | -39.21 | -25.28 | -26.49 | -35.22 |
Interest Expense | -0.84 | -0.87 | -0.02 | -0.06 | - |
Interest & Investment Income | 0.14 | 0.54 | 0.63 | 0.19 | 0.32 |
Earnings From Equity Investments | -2.19 | -1.19 | -0.05 | -0.85 | - |
Currency Exchange Gain (Loss) | -2.16 | -0.19 | 0.2 | 3.24 | 0.32 |
Other Non Operating Income (Expenses) | 0.02 | 0.19 | 0.76 | 0.04 | 0.09 |
EBT Excluding Unusual Items | -47.88 | -40.74 | -23.75 | -23.93 | -34.49 |
Gain (Loss) on Sale of Investments | -0.18 | 1.7 | -2.59 | -3.57 | 4.8 |
Gain (Loss) on Sale of Assets | - | 0.48 | - | -2.06 | -0.07 |
Asset Writedown | - | -0.7 | - | -8.72 | - |
Other Unusual Items | - | - | - | - | 0.47 |
Pretax Income | -48.06 | -39.26 | -26.34 | -38.28 | -35.84 |
Income Tax Expense | - | - | -0.08 | 1.98 | - |
Earnings From Continuing Operations | -48.06 | -39.26 | -26.26 | -40.26 | -35.84 |
Minority Interest in Earnings | - | - | -0.68 | -0.76 | -0.81 |
Net Income | -48.06 | -39.26 | -26.94 | -41.01 | -36.65 |
Preferred Dividends & Other Adjustments | - | - | 0.02 | - | - |
Net Income to Common | -48.06 | -39.26 | -26.96 | -41.01 | -36.65 |
Shares Outstanding (Basic) | 19 | 15 | 13 | 14 | 14 |
Shares Outstanding (Diluted) | 19 | 15 | 13 | 14 | 14 |
Shares Change (YoY) | 20.85% | 14.82% | -2.10% | 0.27% | 23.23% |
EPS (Basic) | -2.59 | -2.56 | -2.02 | -3.01 | -2.69 |
EPS (Diluted) | -2.59 | -2.56 | -2.02 | -3.01 | -2.69 |
Free Cash Flow | -20.77 | -29.45 | -20.17 | -26.7 | -35.79 |
Free Cash Flow Per Share | -1.12 | -1.92 | -1.51 | -1.96 | -2.63 |
Gross Margin | 48.65% | 39.06% | 59.19% | 63.28% | 58.38% |
Operating Margin | -206.87% | -137.41% | -74.62% | -61.45% | -116.74% |
Profit Margin | -232.03% | -137.57% | -79.58% | -95.14% | -121.50% |
Free Cash Flow Margin | -100.28% | -103.19% | -59.54% | -61.94% | -118.63% |
EBITDA | -41.59 | -36.88 | -21.54 | -24.07 | -33.4 |
EBITDA Margin | -200.80% | -129.24% | -63.58% | -55.84% | -110.72% |
D&A For EBITDA | 1.26 | 2.33 | 3.74 | 2.42 | 1.82 |
EBIT | -42.85 | -39.21 | -25.28 | -26.49 | -35.22 |
EBIT Margin | -206.86% | -137.41% | -74.62% | -61.45% | -116.74% |
Revenue as Reported | - | - | - | 43.11 | 30.17 |